Patents by Inventor Laura Jenelle Blair

Laura Jenelle Blair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HSP90 activator AHA1 drives production of pathological tau aggregates
    Patent number: 11931373
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: March 19, 2024
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES
    Publication number: 20220241309
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 4, 2022
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • Transgenic mouse model for conditional FKBP51 expression and related methods
    Patent number: 10814015
    Abstract: The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human FKBP51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline transactivator (tTA) operably linked to a promoter; wherein the tTA is expressed upon activation of the promoter and binds the tetracycline response element, thereby causing expression of FKBP51. The invention also pertains to methods for screening for agents for the prevention and/or treatment of psychiatric disorders, such as depression.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: October 27, 2020
    Assignee: University of South Florida
    Inventors: Chad Dickey, Bo Zhang, Laura Jenelle Blair
  • TRANSGENIC MOUSE MODEL FOR CONDITIONAL FKBP51 EXPRESSION AND RELATED METHODS
    Publication number: 20170258940
    Abstract: The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human FKBP51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline transactivator (tTA) operably linked to a promoter; wherein the tTA is expressed upon activation of the promoter and binds the tetracycline response element, thereby causing expression of FKBP51. The invention also pertains to methods for screening for agents for the prevention and/or treatment of psychiatric disorders, such as depression.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 14, 2017
    Applicant: University of South Florida
    Inventors: Chad Dickey, Bo Zhang, Laura Jenelle Blair
  • TRANSGENIC MOUSE MODEL FOR CONDITIONAL FKBP51 EXPRESSION AND RELATED METHODS
    Publication number: 20150327523
    Abstract: The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human FKBP51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline transactivator (tTA) operably linked to a promoter; wherein the tTA is expressed upon activation of the promoter and binds the tetracycline response element, thereby causing expression of FKBP51. The invention also pertains to methods for screening for agents for the prevention and/or treatment of psychiatric disorders, such as depression.
    Type: Application
    Filed: May 13, 2014
    Publication date: November 19, 2015
    Applicant: University of South Florida
    Inventors: Chad Dickey, Bo Zhang, Laura Jenelle Blair